NCT04447716View on ClinicalTrials.gov

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

May 16, 2024

Study Completion Date

April 30, 2027

Conditions
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Indolent Adult Non-Hodgkin LymphomaRecurrent Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Follicular LymphomaRefractory Indolent Adult Non-Hodgkin LymphomaRefractory Marginal Zone Lymphoma
Interventions
DRUG

Venetoclax

Given PO

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Rituximab

Given IV

BIOLOGICAL

Rituximab and Hyaluronidase Human

Given SC

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Thomas Jefferson University

OTHER